Citations

Clear

1011 citation(s) found for "Barry, WT".

Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years
French, Jacqueline A. , Cleary, Elena, Dlugos, Dennis , Farfel, Gail, Farrell, Kathleen , Grzeskowiak, Caitlin L. , Gurrell, Rachel , Harden, Cynthia L., Stalvey, Tracy, Tsai, Julia , Blum, David , Fountain, Nathan B. , Grzeskowiak, Caitlin L , Wirrell, Elaine C , Fountain, Nathan , French, Jacqueline , Gidal, Barry E. , Wirrell, Elaine

Mayo Clinic

Epilepsia | July 15, 2022 | Volume: 63 | Issue: 10 | Pages: 2664-2670

10.1111/epi.17366 | PMID 35835554 Get It

AbstractObjectivesDrug treatment for children with epilepsy should, ideally, be governed by evidence from adequate and well‐controlled clinical studies. However, these studies are difficult to conduct, and so direct evidence supporting the informed use of specific drugs is often lacking. The Research Roundtable for Epilepsy (RRE) met in 2020 to align on an approach to therapy development for focal seizures in children age 1 month <2 years of age.MethodsThe RRE reviewed the regulatory landscape, epidemiology, seizure semiology, antiseizure medicine pharmacology, and safety issues applicable to this population.ResultsAfter reviewing evidence, the conclusion was that pediatric efficacy trials would be impracticable to conduct but a waiver of the regulatory requirement to conduct any study would lead to an absence of information to guide dosing in a critical population. Review of available data and discussion of RRE attendees led to the conclusion that the requirements for extrapolation of efficacy from older children down to infants from age 1 month to <2 years old appeared to be met. After the RRE, the US Food and Drug Administration (FDA) approved brivaracetam for use in children with focal epilepsy above the age of 1 month in August 2021 and lacosamide in October 2021, both based on the principle of extrapolation from data in older children.SignificanceThese recommendations should result in more rapid accessibility of antiseizure medications for infants.
Exercise Testing in Heart Failure with Preserved Ejection Fraction: An Appraisal Through Diagnosis, Pathophysiology and Therapy – A Clinical Consensus Statement of the Heart Failure Association and European Association of Preventive Cardiology of the Europ
Wilhelm, Matthias , Craenenbroeck, Emeline M. Van , Boer, Rudolf A. de , Lund, Lars H. , Mancini, Donna , Filippatos, Gerasimos , Borlaug, Barry, de Boer, Rudolf A , Wilhelm, Matthias , Guazzi, Marco , Halle, Martin , Kemps, Hareld , Coats, Andrew J.S. , Borlaug, Barry A. , Pieske, Burkert

Mayo Clinic

European Journal of Heart Failure | July 1, 2022 | Volume: 24 | Issue: 8 | Pages: 1327-1345

10.1002/ejhf.2601 | PMID 35775383 Get It

Abstract Patients with heart failure with preserved ejection fraction (HFpEF) universally complain of exercise intolerance and dyspnoea as key clinical correlates. Cardiac as well as extracardiac components play a role for the limited exercise capacity, including an impaired cardiac and peripheral vascular reserve, a limitation in mechanical ventilation and/or gas exchange with reduced pulmonary vascular reserve, skeletal muscle dysfunction and iron deficiency/anaemia. Although most of these components can be differentiated and quantified through gas exchange analysis by cardiopulmonary exercise testing (CPET), the information provided by objective measures of exercise performance has not been systematically considered in the recent algorithms/scores for HFpEF diagnosis, by neither European nor US groups. The current clinical consensus statement by the Heart Failure Association (HFA) and European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology (ESC) aims at outlining the role of exercise testing and its pathophysiological, clinical and prognostic insights, addressing the implications of a thorough functional evaluation from the diagnostic algorithm to the pathophysiology and treatment perspectives of HFpEF. Along with these goals, we provide a specific analysis of the evidence that CPET is the standard for assessing, quantifying, and differentiating the origin of dyspnoea and exercise impairment and even more so when combined with echocardiography and/or invasive haemodynamic evaluation. This will lead to improved quality of diagnosis when applying the proposed scores and may also help to implement the progressive characterization of the specific HFpEF phenotypes, a critical step toward the delivery of phenotype-specific treatments.
Surgical versus catheter ablation in atrial fibrillation: A systematic review and meta‐analysis of randomized controlled trials
Kanitsoraphan, Chanavuth , Kewcharoen, Jakrin , Sriramoju, Anil, Shanbhag, Anusha , Ko, Nway L. Ko, Barry, Timothy , Vutthikraivit, Wasawat , Shen, Win‐Kuang , Rattanawong, Pattara , Kanitsoraphan, Chanavuth , Kewcharoen, Jakrin , Ko Ko, Nway L, Vutthikraivit, Wasawat , Rattanawong, Pattara , Sriramoju, Anil

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 30, 2022 | Volume: 33 | Issue: 10 | Pages: 2152-2163

10.1111/jce.15617 | PMID 35771487 Get It

AbstractIntroductionAtrial fibrillation (AF) is the most common cardiac arrhythmia with a high stroke and mortality rate. The video‐assisted thoracoscopic radiofrequency pulmonary vein ablation is a treatment option for patients who fail catheter ablation. Randomized data comparing surgical versus catheter ablation are limited. We performed a meta‐analysis of randomized control trials to explore the outcome efficacy between surgical and catheter radiofrequency pulmonary vein ablation in patients with AF.MethodsWe comprehensively searched the databases of MEDLINE and EMBASE from inception to December 2020. Included studies were published randomized control trials that compared video‐assisted thoracoscopic and catheter radiofrequency pulmonary vein ablation. Data from each study were combined using the fixed‐effects, generic inverse variance method of DerSimonian, and Laird to calculate odds ratios and 95% confidence intervals.ResultsSix studies from November 2013 to 2020 were included in this meta‐analysis involving 511 AF patients (79% paroxysmal) with 263 catheter ablation (mean age 56 ± 3 years) and 248 surgical ablations (mean age 52 ± 4 years). Catheter ablation was associated with increased atrial arrhythmias recurrence when compared to surgical ablation (pooled relative risk = 1.85, 95% confidence interval: 1.44−2.39, p < .001, I2 = 0.0%) but associated with less total major adverse events (pooled relative risk = 0.29, 95% confidence interval: 0.16−0.53, p < .001, I2 = 0.0%). In subgroup analysis, catheter ablation was associated with increased AF recurrence in refractory paroxysmal AF when compared to surgical ablation (pooled relative risk = 2.47, 95% confidence interval: 1.31−4.65, p = .005, I2 = 0.0%) but not in persistent AF (relative risk = 1.09, 95% confidence interval: 0.60−2.0, p = .773).ConclusionCatheter ablation was associated with higher atrial arrhythmia recurrence when compared with surgical ablation. However, our study suggests that the benefit of surgical ablation in patients with persistent AF is unclear. More studies and alternative ablation strategies investigation in persistent AF are warranted.
Post-operative atrial fibrillation and risk of heart failure hospitalization
Goyal, Parag , Kim, Michael , Krishnan, Udhay , McCullough, Stephen , Cheung, Jim W. , Kim, Luke K. , Pandey, Ambarish , Horn, Evelyn M. , Safford, Monika M. , Mccullough, Stephen A , Horn, Evelyn M , Cheung, Jim W , Kim, Michael , Pandey, Ambarish , Borlaug, Barry A. , Kamel, Hooman

Mayo Clinic

European Heart Journal | June 28, 2022 | Volume: 43 | Issue: 31 | Pages: 2971-2980

10.1093/eurheartj/ehac285 | PMID 35764099 Get It

Abstract Aims Post-operative atrial fibrillation (POAF) is associated with stroke and mortality. It is unknown if POAF is associated with subsequent heart failure (HF) hospitalization. This study aims to examine the association between POAF and incident HF hospitalization among patients undergoing cardiac and non-cardiac surgeries. Methods and results A retrospective cohort study was conducted using all-payer administrative claims data that included all non-federal emergency department visits and acute care hospitalizations across 11 states in the USA. The study population included adults aged at least 18 years hospitalized for surgery without a prior diagnosis of HF. Cox proportional hazards regression models were used to examine the association between POAF and incident HF hospitalization after making adjustment for socio-demographics and comorbid conditions. Among 76 536 patients who underwent cardiac surgery, 14 365 (18.8%) developed incident POAF. In an adjusted Cox model, POAF was associated with incident HF hospitalization [hazard ratio (HR) 1.33; 95% confidence interval (CI) 1.25–1.41]. In a sensitivity analysis excluding HF within 1 year of surgery, POAF remained associated with incident HF hospitalization (HR 1.15; 95% CI 1.01–1.31). Among 2 929 854 patients who underwent non-cardiac surgery, 23 763 (0.8%) developed incident POAF. In an adjusted Cox model, POAF was again associated with incident HF hospitalization (HR 2.02; 95% CI 1.94–2.10), including in a sensitivity analysis excluding HF within 1 year of surgery (HR 1.49; 95% CI 1.38–1.61). Conclusions Post-operative atrial fibrillation is associated with incident HF hospitalization among patients without prior history of HF undergoing both cardiac and non-cardiac surgeries. These findings reinforce the adverse prognostic impact of POAF and suggest that POAF may be a marker for identifying patients with subclinical HF and those at elevated risk for HF.
13 The long-term effects of adipose depot change following bariatric surgery on cardiac geometry
Henry, John A. , Abdesselam, Inès, Sorimachi, Hidemi, Rayner, Jenny, Deal, Oscar , Byrne, James V. , Byrne, James, Neubauer, Stefan , Borlaug, Barry A. , Rider, Oliver J.

Mayo Clinic

ACHD/Valve disease/Pericardial disease/Cardiomyopathy | June 6, 2022 | Volume: No volume available | Issue: No issue available | Pages: A11.1-A11

10.1136/heartjnl-2022-bcs.13 Get It

Multi‐disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post‐acute sequelae of SARS‐CoV‐2 infection (PASC)
Barry, John T., Bartels, Matthew N. , Fleming, Talya K. , McCauley, Mark , Neal, Jacqueline D., Pillarisetti, Jayasree , Sampsel, Sarah , Terzic, Carmen M., Tosto, Jenna, Fleming, Talya K , Sampsel, Sarah , Verduzco-Gutierrez, Monica , Whiteson, Jonathan H. , Azola, Alba Miranda , Blitshteyn, Svetlana , Silver, Julie K. , Verduzco‐Gutierrez, Monica , Putrino, David F.

Mayo Clinic

PM&R | June 3, 2022 | Volume: 14 | Issue: 7 | Pages: 855-878

10.1002/pmrj.12859 | PMID 35657351 Get It

Association between Physical Activity and Chronotropic Incompetence in Patients with Complex Congenital Heart Disease
Kim, Hyun Jeong , Yoon, Ja Kyung , Kim, Chul-Ho, Kim, Seong Ho , Franklin, Barry A. , Jae, Sae Young , Kim, Chul-Ho

Mayo Clinic

The Korean Journal of Sports Medicine | June 2, 2022 | Volume: 40 | Issue: 2 | Pages: 86-93

10.5763/kjsm.2022.40.2.86 Get It

Sex and central obesity in heart failure with preserved ejection fraction
Sorimachi, Hidemi, Omote, Kazunori , Popović, Dejana , Verbrugge, Frederik H. , Reddy, Yogesh N.V. , Lin, Grace , Miles, John M. , Jensen, Michael D. , Obokata, Masaru , Nishimura, Rick , Verbrugge, Frederik H , Omar, Massar , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | May 23, 2022 | Volume: 24 | Issue: 8 | Pages: 1359-1370

10.1002/ejhf.2563 | PMID 35599453 Get It

Abstract Aims Obesity is a risk factor for heart failure with preserved ejection fraction (HFpEF), particularly in women, but the mechanisms remain unclear. The present study aimed to investigate the impact of central adiposity in patients with HFpEF and explore potential sex differences. Methods and results A total of 124 women and 105 men with HFpEF underwent invasive haemodynamic exercise testing and rest echocardiography. Central obesity was defined as a waist circumference (WC) ≥88 cm for women and ≥102 cm for men. Exercise‐normalized pulmonary capillary wedge pressure (PCWP) responses were evaluated by the ratio of PCWP to workload (PCWP/W) and after normalizing to body weight (PCWL). The prevalence of central obesity (77%) exceeded that of general obesity (62%) defined by body mass index ≥30 kg/m 2 . Compared to patients without central adiposity, patients with HFpEF and central obesity displayed greater prevalence of diabetes and dyslipidaemia, higher right and left heart filling pressures and pulmonary artery pressures during exertion, and more severely reduced aerobic capacity. Associations between WC and fasting glucose, low‐density lipoprotein (LDL) cholesterol, peak workload, and pulmonary artery pressures were observed in women but not in men with HFpEF. Although increased WC was associated with elevated PCWP in both sexes, the association with PCWP/W was observed in women but not in men. The strength of correlation between PCWP/W and WC was more robust in women with HFpEF as compared to men (Meng's test p = 0.0008), and a significant sex interaction was observed in the relationship between PCWL and WC ( p for interaction = 0.02). Conclusions Central obesity is even more common than general obesity in HFpEF, and there appear to be important sexual dimorphisms in its relationships with metabolic abnormalities and haemodynamic perturbations, with greater impact in women.